Dzvanya apa kuti uratidze mabhena ako pane ino peji uye ungobhadhara chete kubudirira

Nhau dzeWaya

Mutsva Antibody Anogona Neutralize Omicron uye Variants

rakanyorwa mupepeti

Sorrento Therapeutics, Inc. nhasi yazivisa kuburitswa kwedata idzva paOmicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, antibody yepadanho repamusoro yakawanikwa uye yakagadziridzwa kuti iedze kiriniki mukubatana kunoramba kuripo pakati pevanoongorora immunospyware nehutachiona hwehutachiona kuSorrento neIcahn. Chikoro cheMishonga paGomo reSinai muNew York, NY.

Spike protein inosunga assays uye neutralization assays vachishandisa mavhairasi anomiririra ese anozivikanwa SARS-CoV-2 akasiyana ekunetsekana (VOCs) apedzwa neSTI-9167, uye iyi nAb yakacherechedzwa kuti inosunga nehukama hwepamusoro uye inopa yakanyanya simba yekusagadzikana chiitiko (Omicron IC50 = 25 ng/ml). Zvekukosha zvinozivikanwa, STI-9167 yakasarudzika kana ichienzaniswa nemiedzo yeEUA-yakatenderwa SARS-CoV-2 nAbs mune inosunga uye kusarerekera zvivakwa zvinochengetwa zvichipesana neari kubuda Omicron uye Omicron (+R346K) musiyano, unowedzera kuwanda kweOmicron mutsara wemutsara iwoyo. inoisa imwe R346K Spike protein mutation. Pamusoro pezvo, STI-9167 inopihwa padanho rakaderera (5mg/kg) neinopinza kana intravenous nzira dzakapa dziviriro yakasimba kubva kuzviratidzo zvekiriniki zvekutapukirwa neOmicron musiyano muK18-hAce2 transgenic mbeva modhi yeCOVID-19, kudzivirira huremu. kurasikirwa uye kuderedza hutachiona hwehutachiona mumapapu kusvika kumazinga asingaonekwe.

"Chizvarwa uye chimiro cheSTI-9167 nAb chinoratidza kubatana kukuru pakati pemasayendisiti eGomo reSinai neSorrento kugadzirisa dambudziko rehutano pasi rose," akadaro Domenico Tortorella, PhD, Purofesa weMicrobiology paIcahn Mount Sinai.

"Takasarudza antibody STI-9167 kubva kumaseti akakura emhando dzakasiyana-siyana dzeAnti-SARS-CoV-2 spike neutralizing antibodies dzatakagadzira mumalabhu edu. Yakaratidza kuchinjika-kuneutralization kunoshanda kune ese anozivikanwa SARS-CoV-2 akasarudzika uye akasiyana ezvinetseke, kusanganisira ichangoburwa Omicron uye Omicron (+R346K) akasiyana," akadaro J. Andrew Duty, PhD, Mubatsiri Purofesa weMicrobiology uye Director we iyo Center for Therapeutic Antibody Development paIcahn Mount Sinai.

"Parizvino EUA-inotenderwa nAbs yakadzikisa zvakanyanya kana kusavapo inosunga uye kusarerekera kuita zvinhu zvinopesana neomicron/omicron (+R346K) zvichiita kuti dzisakwane kutsigira zvinodiwa nekiriniki zvazvino," akadaro Mike A. Royal, MD, JD, MBA, Chief Medical Officer pa. Sorrento. “Alternative nAbs inodiwa zvakanyanya munguva pfupi iri kutevera, kunyanya kunhamba yevana inoratidzika kunge iri panjodzi huru yekutapukirwa neomicron zvakanyanya uye kuchipatara. Yedu intranasal COVIDROPS maumbirwo anoendesa nAbs yedu kunzira dzekumusoro dzemhepo uko Omicron ingangoita kunanga uye kubudirira, uye seisingapindike, iri nyore kurapa kurapwa, yakanakira vana. Takatotanga kurapa vana neCCIDROPS (ine STI-2099) kuMexico uko musiyano wedelta uchiri kuwanda. Kuburikidza nezvidzidzo zveChikamu 2 muUS, United Kingdom neMexico, takaona chimiro chekuchengetedza chekuchengetedza mumhino yeAbs yedu uye tinotarisira mhedzisiro yakafanana neCCIDROP (ine STI-9167).

"Isu tave neruzivo mukuunza akawanda eCCIDID-19 marapirwo mukiriniki uye nekusimudzira akati wandei muChikamu 2 uye / kana budiriro yakakosha," anodaro Mark Brunswick, PhD, SVP uye Musoro weRegulatory Affairs uye Hunhu kuSorrento. "Isu tagara zvakanaka kukurumidza kuburitsa COVISHIELD kuburikidza neIND nhanho uye mukiriniki uye tinotarisira kuisa iyi yakakosha IND mumwedzi unotevera."

Dr. Henry Ji, Sachigaro uye CEO weSorrento, vakati, "Basa rakaitwa nezvikwata zveSorrento neGomo reSinai rakaburitsa antibody inoshamisa ine yakasarudzika uye yakakosha zvidziviriro kubva kuOmicron nemamwe ese maSARS-CoV-2 VOC. Yedu COVISHIELD neutralizing antibody ndiye akanakisa-mu-kirasi uye akanyanya kukwikwidza kurwisa iyo yakapararira Omicron uye ari kusimukira Omicron (+R346K) VOCs. Tiri kushanda nesimba kuti tiise antibody iyi kuti ishandiswe muvarwere veCCIDIDs uye tine chivimbo chekuti nzira yedu ichapa mhinduro inoshanda yekiriniki kwete munguva pfupi chete asiwo sezvo denda riri kuramba richiitika. "

A preprint manuscript yakatumirwa muna Ndira 19, 2022 uye ichaburitswa munguva pfupi irimo online pa biorxiv.org.

Antibody inodzivirira yakatsanangurwa yakagadzirwa mumarabhoritari paGomo reSinai uye yakapihwa rezenisi reSorrento Therapeutics. Gomo reSinai uye nhengo dzedare reGomo reSinai dzine chido chemari muSorrento Therapeutics.

Nhau Dzakabatana

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment

Govera ku...